drugset / Trial / NCT00819637

A Pilot Study to Determine the Most Effective Dose of Arformoterol for Treating Acute Asthmatic Patients

NCT00819637

RandomizedParallel-groupQuadruple-blindTreatment

Summary

The purpose of this study is to determine the best dose of nebulized arformoterol, a quick onset but long acting beta agonist, for use in treating acute bronchospasm in asthmatics presenting to the the Emergency Department. Also this study will evaluate the side effect and safety profile of arformoterol when used in this situation.

Timeline

Start
2009-01
Primary completion
2009-11
Completion
2009-11

Drugs

EvaluationDrugModalityDoseRoute
Subject Arformoterol Small molecule 15 ug Inhaled
Comparator Levalbuterol Other / unclassified 1.25 mg Inhaled

Indications